Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Fauci slams U.K.'s speedy review of Pfizer, BioNTech COVID-19 shot
HHS enlists CVS to pilot administering Eli Lilly's antibody drug to high-risk patients
Not just AstraZeneca: Hackers targeted 5 other COVID-19 drug developers, vaccine cold chain suppliers
Sponsored: Predicting Landfall: A Dynamic Control Room for Taking on the COVID-19 Landscape
FDA's Hahn defends pace of Pfizer COVID-19 vaccine review
Your patient plans to travel despite COVID-19 risk? Here's the latest CDC guidance to share
COVID-19 vaccines based on novel platforms show early promise in mice
As COVID demand surges, BD blueprints $1.2B expansion to jack up prefilled syringe output by 50%
Biopharma roundup: Dry ice, syringe makers respond to skyrocketing demand; Inovio inks manufacturing deal
Banner Health posts $57.2M loss since start of 2020 but reports improving income from operations
British health tech startup uMed raises cash for next-gen clinical trial work

Featured Story

Fauci slams U.K.'s speedy review of Pfizer, BioNTech COVID-19 shot

By Eric Sagonowsky

The U.K.’s monumental approval for Pfizer and BioNTech’s COVID-19 vaccine turned heads worldwide, but one of the leading voices in the U.S. pandemic response argues the country’s regulators acted too quickly.

HHS enlists CVS to pilot administering Eli Lilly's antibody drug to high-risk patients

By Paige Minemyer

The Trump administration has purchased an additional 650,000 doses of Eli Lilly's antibody treatment for COVID-19 and enlisted CVS Health to pilot administering the therapy to patients in long-term care facilities and at home.

Not just AstraZeneca: Hackers targeted 5 other COVID-19 drug developers, vaccine cold chain suppliers

By Angus Liu

A few days ago, allegations were made against North Korean hackers for cyberattacking COVID-19 vaccine frontrunner AstraZeneca. Turns out, the British pharma wasn’t alone on Pyeongyang’s hunting list, which also included Johnson & Johnson, Novavax and three South Korean firms, according to The Wall Street Journal.

FDA Commissioner Stephen Hahn, M.D., has defended the pace of the review of Pfizer’s COVID-19 vaccine on the grounds that a thorough assessment is needed to reassure a skeptical public.

Your patient plans to travel despite COVID-19 risk? Here's the latest CDC guidance to share

By Tina Reed

Make no mistake: Federal officials recommend the American public stay home over the upcoming holidays in order to stem surges of the COVID-19 pandemic. But if an individual does plan to travel, here's how the CDC is advising public health officials.

COVID-19 vaccines based on novel platforms show early promise in mice

By Angus Liu

Even as mRNA COVID-19 vaccines are advancing to market, researchers continue to look for alternative—and possibly better—options. Now, two teams from City of Hope and Canadian biotech Biovaxys Technology have reported positive animal data for their candidates that come from different technology platforms.

COVID-19 Tracker

Featured Story

Fauci slams U.K.'s speedy review of Pfizer, BioNTech COVID-19 shot

Top Stories

HHS enlists CVS to pilot administering Eli Lilly's antibody drug to high-risk patients

Not just AstraZeneca: Hackers targeted 5 other COVID-19 drug developers, vaccine cold chain suppliers

Sponsored: Predicting Landfall: A Dynamic Control Room for Taking on the COVID-19 Landscape

FDA's Hahn defends pace of Pfizer COVID-19 vaccine review

Your patient plans to travel despite COVID-19 risk? Here's the latest CDC guidance to share

COVID-19 vaccines based on novel platforms show early promise in mice

As COVID demand surges, BD blueprints $1.2B expansion to jack up prefilled syringe output by 50%

Biopharma roundup: Dry ice, syringe makers respond to skyrocketing demand; Inovio inks manufacturing deal

Banner Health posts $57.2M loss since start of 2020 but reports improving income from operations

British health tech startup uMed raises cash for next-gen clinical trial work